Career Center
Trending on CancerNetwork
A New Era of Personalized Cancer Therapeutics at ESMO
BELLWAVE Program for Nemtabrutinib Discontinued After Phase 3 CLL/SLL Trial
FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers
ET Adherence Raises Cardiometabolic Risk, Improves Survival in HR+ Breast Cancer
BHV-1530 Shows Responses in FGFR3-Altered Urothelial and Head and Neck Cancers
Latest News
Shorts










Videos
Continuing Medical Education
All News

The FDA granted priority review to sonesitatug vedotin in second- and later-line CLDN18.2-positive gastric, GEJ, or esophageal adenocarcinoma, with a decision expected in the second quarter of 2027.

An external data monitoring committee noted that nemtabrutinib’s benefits in first-line CLL/SLL may not outweigh its risks in the phase 3 BELLWAVE-011 trial.

Five-year AI adherence was tied to more hypertension, dyslipidemia, and diabetes in HR+ breast cancer, yet adherence also lowered all-cause mortality.

Partial responses occurred in 6 of 10 evaluable patients with FGFR3-altered tumors treated with BHV-1530, an FGFR3-directed antibody-drug conjugate, in a phase 1 study.

Amir T. Fathi, MD, outlines what menin inhibitors must show for frontline approval and how to manage differentiation syndrome.

Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

In the phase 1/2 TRANSCEND CLL 004 trial, liso-cel plus ibrutinib produced a 45% CR/CRi rate in a heavily pretreated relapsed/refractory CLL/SLL population.

The FDA has assigned a target action date of June 28, 2027, for selinexor plus ruxolitinib as a therapeutic regimen for patients with myelofibrosis.

In the phase 2 TRAP trial, the median PFS after SBRT was 3.0 months with detectable ctDNA vs 7.8 months without it in oligoprogressive CRPC.

In the pivotal phase 3 REGAL trial, galinpepimut-S was generally well tolerated among patients with acute myeloid leukemia.

Amir T. Fathi, MD, discusses where venetoclax/azacitidine fits in fit patients with AML and why a phase 3 trial may be unlikely.

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

After an FDA Type C meeting, registrational trials of the DLL3-targeting ADC IDE849 in pretreated neuroendocrine carcinomas are set to begin by year-end.

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

The American Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which may help advance research and care.

At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.

The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer based on data from the phase 3 evERA trial.

Martin Gleave, CM, MD, FRCSC, FACS, discussed perioperative therapy selection, the GUNS trial, and postoperative radiotherapy in prostate cancer.

In OptimUM-01, darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in untreated metastatic uveal melanoma, regardless of HLA status.

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.

The CHMP recommended belzutifan plus lenvatinib for advanced clear cell RCC after anti–PD-(L)1 therapy, based on phase 3 LITESPARK-011 data.

Adjuvant cretostimogene reduced recurrence risk by 68% vs surveillance in intermediate-risk and high-grade Ta NMIBC in the phase 3 PIVOT-006 trial.

The FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
































































